Epidemiology of Immune-Mediated Glomerulopathies before and after SARS-CoV-2 Vaccination: A Tertiary Referral Hospital Experience

• Published in: Journal of clinical medicine Vol. 12; no. 6; p. 2420
• Main Authors: Zamora, Jorge Iván, López-Martínez, Marina, Patricio Liebana, Marc, Leon Román, Juan Carlos, Bermejo, Sheila, Vergara, Ander, Agraz, Irene, Terrades, Natalia Ramos, Azancot, Maria Antonieta, Toapanta, Nestor, Gabaldon, Maria Alejandra, Soler, Maria José
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21-03-2023; MDPI
• Subjects: Biopsy; Clinical medicine; Coronaviruses; COVID-19 vaccines; Creatinine; Disease; Glomerulonephritis; Guillain-Barre syndrome; Hematuria; Immunization; Infections; Laboratories; Normal distribution; Patients; Prevention; Remission (Medicine); Risk factors; Severe acute respiratory syndrome coronavirus 2; Spain; flare; immune-mediated glomerulopathy; SARS-CoV-2; vaccine
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12062420

Vaccination is a known trigger for the appearance of immune-mediated glomerulopathies (IMG). The appearance of IMG after SARS-CoV-2 vaccination with suspected causality has been described. Our aim is to analyze the incidence of IMG flares before and after SARS-CoV-2 vaccination in our center.
All persons with native kidney biopsy (KB) from January 2019 to March 2022 in our center were included in the study. We compared the incidence of IMG before and after the start of vaccination. We also collected information about whether the patients had received a SARS-CoV-2 vaccine or have suffered from COVID in the six weeks before the IMG. We also evaluated the analytical characteristics of the outbreaks.
A total of 386 KB were studied. Of them, 86/218 (39.4%) were IMG performed pre- and 85/168 (50.6%) post-SV (029). The incidence of idiopathic nephrotic syndrome (INS), studied separately, was also significantly increased post-vaccination (
= 18 (10.7%)) compared to pre-vaccination (
= 11 (5%)) (
= 0.036). There were no differences in the incidence of vasculitis or IgA nephropathy. Up to 17 (20%) flares occurred 6 weeks before SARS-CoV-2 vaccination and only 2 (2.4%) within the first 6 weeks after SARS-CoV-2 infection. Within those 17 flares, the most common diagnosis was IgAN (
= 5 (29.4%)); a total of 14 (82.4%) received an mRNA vaccine and 9 (52.9%) took place after the 1st vaccine dose. There were 13 cases of minimal change disease (MCD) with debut/recurrence pre-SV and 20 MCD with debut/recurrence post-SV (
= 0.002).
The incidence of IMG, INS and MCD flares in our center increased significantly after SARS-CoV-2 vaccination. Importantly, 20% of IMG flares took place within the first 6 weeks after receiving a vaccine dose, with the first dose being the riskiest one and IgAN the most frequent diagnosis.